Overcoming Challenges of Ovarian Cancer Stem Cells: Novel Therapeutic Approaches

被引:37
作者
Aguilar-Gallardo, Cristobal [2 ]
Cecilia Rutledge, Emily [2 ]
Martinez-Arroyo, Ana M. [2 ]
Jose Hidalgo, Juan [3 ]
Domingo, Santiago [3 ]
Simon, Carlos [1 ,2 ]
机构
[1] Univ Valencia, Fdn IVI, Inst Univ IVI, E-46012 Valencia, Spain
[2] Prince Felipe Res Ctr CIPF, Valencia Node Spanish Stem Cell Bank, Valencia, Spain
[3] Univ Hosp La Fe, Valencia, Spain
关键词
Ovarian cancer stem cells; Microenvironment; New therapeutic approaches; ACTIVATED-RECEPTOR-GAMMA; HEPATOCELLULAR-CARCINOMA CELLS; EPITHELIAL OVARIAN; PANCREATIC-CANCER; INITIATING CELLS; PROSPECTIVE IDENTIFICATION; PROGNOSTIC MARKER; DRUG-RESISTANCE; DNA-REPAIR; STAGE-III;
D O I
10.1007/s12015-011-9344-5
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Understanding the genetic and molecular mechanisms of ovarian cancer has been the focus of research efforts working toward the greater goal of improving cancer therapy for patients with residual disease after initial treatment with conventional surgery and neoadjuvant chemotherapy. The focus of this review will be centered on new therapeutic strategies based on Cancer Stem Cells studies of chemoresistant subpopulations, the prevention of metastasis, and individualized therapy in order to find the most successful combination of treatments to effectively treat human ovarian cancer. We reviewed recent literature (1993-2011) of novel treatment approaches to ovarian cancer stem cells. As the focus of ovarian cancer investigation has centered on the cancer stem cell model and the complexities that it presents in the development of effective treatments, the future of treating ovarian cancer lies in utilizing individualized treatment systems that include enhancing existing treatments, aiming for novel therapy targets, managing the plasticity of stem cells to induce cellular differentiation, and regulating oncogenic signaling pathways.
引用
收藏
页码:994 / 1010
页数:17
相关论文
共 174 条
[61]   In vitro metformin anti-neoplastic activity in epithelial ovarian cancer [J].
Gotlieb, Walter H. ;
Saumet, Julio ;
Beauchamp, Marie-Claude ;
Gu, Jing ;
Lau, Susie ;
Pollak, Michael N. ;
Bruchim, Ilan .
GYNECOLOGIC ONCOLOGY, 2008, 110 (02) :246-250
[62]   Up-regulation of gene expression by hypoxia is mediated predominantly by hypoxia-inducible factor 1 (HIF-1) [J].
Greijer, AE ;
van der Groep, P ;
Kemming, D ;
Shvarts, A ;
Semenza, GL ;
Meijer, GA ;
van de Wiel, MA ;
Belien, JAM ;
van Diest, PJ ;
van der Wall, E .
JOURNAL OF PATHOLOGY, 2005, 206 (03) :291-304
[63]   Immunity, Inflammation, and Cancer [J].
Grivennikov, Sergei I. ;
Greten, Florian R. ;
Karin, Michael .
CELL, 2010, 140 (06) :883-899
[64]   Antineoplastic effects of peroxisome proliferator-activated receptor γ agonists [J].
Grommes, C ;
Landreth, GE ;
Heneka, MT .
LANCET ONCOLOGY, 2004, 5 (07) :419-429
[65]   Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening [J].
Gupta, Piyush B. ;
Onder, Tamer T. ;
Jiang, Guozhi ;
Tao, Kai ;
Kuperwasser, Charlotte ;
Weinberg, Robert A. ;
Lander, Eric S. .
CELL, 2009, 138 (04) :645-659
[66]   Hallmarks of Cancer: The Next Generation [J].
Hanahan, Douglas ;
Weinberg, Robert A. .
CELL, 2011, 144 (05) :646-674
[67]   Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties [J].
Hegedus, C. ;
Oezvegy-Laczka, C. ;
Apati, A. ;
Magocsi, M. ;
Nemet, K. ;
Orfi, L. ;
Keri, G. ;
Katona, M. ;
Takats, Z. ;
Varadi, A. ;
Szakacs, G. ;
Sarkadi, B. .
BRITISH JOURNAL OF PHARMACOLOGY, 2009, 158 (04) :1153-1164
[68]   CD44v6: a target for antibody-based cancer therapy [J].
Heider, KH ;
Kuthan, H ;
Stehle, G ;
Munzert, G .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2004, 53 (07) :567-579
[69]   Cellular stress response and apoptosis in cancer therapy [J].
Herr, I ;
Debatin, KM .
BLOOD, 2001, 98 (09) :2603-2614
[70]   Pharmacogenomics of platinum-based chemotherapy in NSCLC [J].
Hildebrandt, Michelle A. T. ;
Gu, Jian ;
Wu, Xifeng .
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2009, 5 (07) :745-755